Park Edge Advisors LLC Increases Position in AbbVie Inc. $ABBV

Park Edge Advisors LLC boosted its holdings in AbbVie Inc. (NYSE:ABBV) by 57.9% in the fourth quarter, according to its most recent Form 13F filing with the SEC. The fund owned 9,253 shares of the company’s stock after purchasing an additional 3,394 shares during the period. Park Edge Advisors LLC’s holdings in AbbVie were worth $2,114,000 at the end of the most recent reporting period.

A number of other hedge funds have also recently bought and sold shares of ABBV. Evolution Wealth Management Inc. acquired a new position in shares of AbbVie in the 2nd quarter valued at approximately $26,000. Chelsea Counsel Co. acquired a new stake in shares of AbbVie during the third quarter worth approximately $26,000. Westend Capital Management LLC bought a new stake in shares of AbbVie in the fourth quarter worth $29,000. Texas Capital Bancshares Inc TX bought a new stake in shares of AbbVie in the third quarter worth $31,000. Finally, Caitlin John LLC acquired a new stake in AbbVie in the third quarter valued at $33,000. Institutional investors and hedge funds own 70.23% of the company’s stock.

Wall Street Analyst Weigh In

Several research analysts have weighed in on ABBV shares. HSBC raised shares of AbbVie from a “hold” rating to a “buy” rating and raised their price objective for the stock from $225.00 to $265.00 in a report on Wednesday, December 10th. Evercore reduced their price target on shares of AbbVie from $232.00 to $228.00 and set an “outperform” rating on the stock in a research report on Wednesday, February 4th. Morgan Stanley lifted their price target on AbbVie from $269.00 to $270.00 and gave the stock an “overweight” rating in a research note on Thursday, February 5th. Guggenheim reissued a “buy” rating on shares of AbbVie in a report on Thursday, March 12th. Finally, The Goldman Sachs Group restated a “neutral” rating and set a $223.00 price objective on shares of AbbVie in a research note on Wednesday, January 28th. Two research analysts have rated the stock with a Strong Buy rating, fourteen have assigned a Buy rating and nine have issued a Hold rating to the company’s stock. Based on data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus target price of $253.15.

AbbVie Stock Performance

Shares of NYSE:ABBV opened at $208.79 on Friday. The company’s fifty day moving average is $221.79 and its two-hundred day moving average is $224.48. AbbVie Inc. has a 1-year low of $164.39 and a 1-year high of $244.81. The stock has a market capitalization of $369.17 billion, a price-to-earnings ratio of 88.47, a price-to-earnings-growth ratio of 0.75 and a beta of 0.38.

AbbVie (NYSE:ABBV) last posted its quarterly earnings results on Wednesday, February 4th. The company reported $2.71 EPS for the quarter, beating the consensus estimate of $2.65 by $0.06. AbbVie had a net margin of 6.91% and a negative return on equity of 1,579.75%. The business had revenue of $16.62 billion during the quarter, compared to analyst estimates of $16.39 billion. During the same period in the previous year, the business posted $2.16 EPS. The company’s quarterly revenue was up 10.0% on a year-over-year basis. AbbVie has set its FY 2026 guidance at 14.370-14.570 EPS and its Q1 2026 guidance at 2.970-3.010 EPS. Sell-side analysts expect that AbbVie Inc. will post 12.31 EPS for the current fiscal year.

AbbVie Announces Dividend

The business also recently announced a quarterly dividend, which will be paid on Friday, May 15th. Stockholders of record on Wednesday, April 15th will be issued a dividend of $1.73 per share. The ex-dividend date of this dividend is Wednesday, April 15th. This represents a $6.92 annualized dividend and a dividend yield of 3.3%. AbbVie’s dividend payout ratio is 293.22%.

Insider Buying and Selling

In related news, SVP David Ryan Purdue sold 5,230 shares of the company’s stock in a transaction on Wednesday, March 4th. The stock was sold at an average price of $233.56, for a total transaction of $1,221,518.80. Following the completion of the transaction, the senior vice president directly owned 2,654 shares in the company, valued at $619,868.24. This represents a 66.34% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, EVP Perry C. Siatis sold 22,381 shares of the stock in a transaction on Wednesday, February 25th. The stock was sold at an average price of $230.00, for a total value of $5,147,630.00. Following the completion of the sale, the executive vice president directly owned 38,137 shares in the company, valued at $8,771,510. This represents a 36.98% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. 0.25% of the stock is currently owned by corporate insiders.

AbbVie Company Profile

AbbVie is a global, research-driven biopharmaceutical company that was created as a spin-off from Abbott Laboratories in 2013 and is headquartered in North Chicago, Illinois. The company focuses on discovering, developing and commercializing therapies for complex and often chronic medical conditions. Its operations span research and development, manufacturing, regulatory affairs and commercialization, with an emphasis on bringing specialty medicines to market across multiple therapeutic areas.

AbbVie’s product portfolio and pipeline cover several major therapeutic categories, including immunology, oncology, neuroscience, virology and women’s health.